Bullfrog AI (NASDAQ:BFRG – Get Free Report) and Pulmonx (NASDAQ:LUNG – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, earnings, dividends and risk.
Earnings & Valuation
This table compares Bullfrog AI and Pulmonx”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bullfrog AI | $60,000.00 | 118.06 | -$6.99 million | ($0.69) | -0.90 |
| Pulmonx | $90.50 million | 0.75 | -$54.00 million | ($1.33) | -1.21 |
Profitability
This table compares Bullfrog AI and Pulmonx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bullfrog AI | N/A | -218.25% | -177.11% |
| Pulmonx | -59.67% | -82.79% | -38.20% |
Institutional & Insider Ownership
1.0% of Bullfrog AI shares are owned by institutional investors. Comparatively, 91.0% of Pulmonx shares are owned by institutional investors. 25.2% of Bullfrog AI shares are owned by company insiders. Comparatively, 6.8% of Pulmonx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Risk and Volatility
Bullfrog AI has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Pulmonx has a beta of 0.07, meaning that its stock price is 93% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and price targets for Bullfrog AI and Pulmonx, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bullfrog AI | 1 | 0 | 0 | 0 | 1.00 |
| Pulmonx | 1 | 3 | 4 | 0 | 2.38 |
Pulmonx has a consensus price target of $5.38, indicating a potential upside of 234.07%. Given Pulmonx’s stronger consensus rating and higher probable upside, analysts plainly believe Pulmonx is more favorable than Bullfrog AI.
About Bullfrog AI
Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.
About Pulmonx
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Receive News & Ratings for Bullfrog AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bullfrog AI and related companies with MarketBeat.com's FREE daily email newsletter.
